Evidence map›Paper›PMID 26601828›Full record

ArticleGut and liver2016

Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus.

Hideyuki Tamai, Naoki Shingaki, Yoshiyuki Mori, Kosaku Moribata, Akira Kawashima, Yoshimasa Maeda, Toru Niwa, Hisanobu Deguchi, Izumi Inoue, Takao Maekita and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hideyuki TamaiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Naoki ShingakiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Yoshiyuki MoriSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Kosaku MoribataSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Akira KawashimaDepartment of Internal Medicine, Naga Municipal Hospital, Wakayama, Japan.
Yoshimasa MaedaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Toru NiwaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Hisanobu DeguchiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Izumi InoueSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Takao MaekitaSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Mikitaka IguchiSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Jun KatoSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Masao IchinoseSecond Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JPNaga Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsThis study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using viral response within 2 weeks.

methodsLow-dose PEG-IFN-α-2b plus ribavirin was administered to 50 elderly and/or cirrhotic patients with genotype 2 HCV for 24 weeks. The dynamics of HCV RNA and HCV core antigen levels within 2 weeks were measured.

resultsThe patients' median age was 66 years. There were 21 male and 29 female patients. The median baseline HCV RNA level was 5.7 log IU/mL. Rapid viral response was achieved in 17 patients (34%), SVR in 28 (56%), and two (4%) discontinued treatment. Univariate analysis of factors contributing to SVR showed significant differences for sex, baseline virus level, and response within 4 weeks. When 40 fmol/L was set as the cutoff value for the core antigen level at 1 week, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for predicting SVR were 93%, 75%, 84%, 88%, and 85%, respectively.

conclusionsLow-dose PEG-IFN plus ribavirin was a safe and costeffective treatment for elderly and/or cirrhotic patients with genotype 2 HCV, and the viral response within 2 weeks was a useful predictor of SVR.

Indexed as

AdultAgedAntiviral AgentsDrug Administration ScheduleDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2Liver CirrhosisMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRibavirinAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirinElderlyHepacivirusLiver cirrhosisPegylated interferonRibavirin

Identifiers

PMID26601828
PMCPMC4933424
OpenAlexW2415793088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.